This inventor holds 1 USPTO granted patent. Top assignees: Centre Hospitalier Régional Universitaire De Tours, National Institute of Health and Medical Research, Universite De Tours. Active years: 2020.
Company Filing History:

Years Active: 2020
Title: Elodie Beaumont: Innovator in Vaccine Development
Introduction
Elodie Beaumont is a prominent inventor based in Ballan-Mire, France. She has made significant contributions to the field of immunology, particularly in the development of vaccines. Her innovative work has led to the creation of a unique fusion protein that has potential applications in vaccine preparation.
Latest Patents
Elodie Beaumont holds a patent for "Fusion proteins and use thereof for preparing vaccines." This immunogenic fusion protein includes two key peptides. The first peptide is derived from the amino acid sequence of the protein S or protein M of a human hepatitis B virus isolate. The second peptide consists of the sequence of amino acids from at least one transmembrane domain and the ectodomain of a Zika virus isolate, specifically selected from the envelope protein E or a fusion peptide that includes both the envelope protein E and the protein prM. She has 1 patent to her name.
Career Highlights
Throughout her career, Elodie has worked with notable institutions such as Université de Tours and Centre Hospitalier Régional Universitaire de Tours. Her work in these organizations has allowed her to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Elodie has collaborated with several professionals, including Christophe Hourioux and Romuald Patient. These partnerships have enhanced her research and development efforts in vaccine technology.
Conclusion
Elodie Beaumont is a trailblazer in the field of vaccine development, with her innovative fusion protein patent paving the way for future advancements. Her contributions to immunology and collaboration with esteemed institutions highlight her commitment to improving public health through scientific innovation.